Abstract
We report two cases where the addition of mibefradil to long term beta-blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.
MeSH terms
-
Adrenergic beta-Antagonists / adverse effects*
-
Aged
-
Benzimidazoles / adverse effects*
-
Bradycardia / chemically induced*
-
Bradycardia / physiopathology
-
Bradycardia / therapy
-
Calcium Channel Blockers / adverse effects*
-
Cardiac Pacing, Artificial
-
Drug Therapy, Combination
-
Electrocardiography
-
Female
-
Humans
-
Mibefradil
-
Middle Aged
-
Tetrahydronaphthalenes / adverse effects*
-
Vasodilator Agents / adverse effects*
Substances
-
Adrenergic beta-Antagonists
-
Benzimidazoles
-
Calcium Channel Blockers
-
Tetrahydronaphthalenes
-
Vasodilator Agents
-
Mibefradil